X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1355) 1355
Publication (146) 146
Newsletter (91) 91
Newspaper Article (60) 60
Book Review (14) 14
Transcript (11) 11
Conference Proceeding (9) 9
Book Chapter (3) 3
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bendamustine (996) 996
humans (864) 864
index medicus (700) 700
oncology (530) 530
hematology (528) 528
rituximab (471) 471
bendamustine hydrochloride (443) 443
male (430) 430
female (425) 425
aged (381) 381
middle aged (380) 380
antineoplastic combined chemotherapy protocols - therapeutic use (337) 337
chemotherapy (326) 326
cancer (294) 294
lymphomas (288) 288
treatment outcome (245) 245
adult (239) 239
care and treatment (232) 232
leukemia, lymphocytic, chronic, b-cell - drug therapy (201) 201
nitrogen mustard compounds - therapeutic use (196) 196
nitrogen mustard compounds - administration & dosage (194) 194
non-hodgkins-lymphoma (184) 184
aged, 80 and over (178) 178
antineoplastic agents - therapeutic use (171) 171
chronic lymphocytic leukemia (171) 171
therapy (168) 168
antineoplastic agents (159) 159
antimitotic agents (153) 153
bendamustine hydrochloride - administration & dosage (151) 151
chronic lymphocytic-leukemia (146) 146
cyclophosphamide (144) 144
open-label (141) 141
multicenter (137) 137
nitrogen mustard compounds - adverse effects (136) 136
antineoplastic combined chemotherapy protocols - adverse effects (135) 135
trial (134) 134
plus rituximab (128) 128
lymphoma (124) 124
pharmacology & pharmacy (124) 124
research (124) 124
bortezomib (123) 123
leukemia (123) 123
fludarabine (122) 122
medicine & public health (121) 121
multiple myeloma (120) 120
recurrence (117) 117
mantle cell lymphoma (116) 116
phase-ii (111) 111
disease-free survival (110) 110
drug therapy (110) 110
1st-line treatment (106) 106
prognosis (106) 106
patients (104) 104
transplantation (104) 104
antineoplastic agents, alkylating - therapeutic use (102) 102
follicular lymphoma (100) 100
rituximab - administration & dosage (100) 100
survival (99) 99
bendamustine plus rituximab (97) 97
antineoplastic combined chemotherapy protocols - administration & dosage (94) 94
clinical trials (94) 94
lymphoma, non-hodgkin - drug therapy (94) 94
analysis (93) 93
antibodies, monoclonal, murine-derived - administration & dosage (93) 93
phase-ii trial (93) 93
lenalidomide (89) 89
lymphoma, mantle-cell - drug therapy (88) 88
bendamustine hydrochloride - therapeutic use (87) 87
stem-cell transplantation (87) 87
combination (85) 85
retrospective studies (83) 83
non-hodgkin's lymphomas (81) 81
progression-free survival (80) 80
animals (79) 79
hematology, oncology and palliative medicine (79) 79
hemic and lymphatic diseases (76) 76
chlorambucil (75) 75
non-hodgkin lymphoma (75) 75
remission induction (74) 74
antineoplastic agents - administration & dosage (73) 73
stem cells (73) 73
toxicity (73) 73
antineoplastic agents - adverse effects (72) 72
efficacy (71) 71
multiple myeloma - drug therapy (71) 71
indolent (70) 70
previously untreated patients (69) 69
salvage therapy (69) 69
apoptosis (68) 68
cll (68) 68
drug administration schedule (67) 67
relapse (67) 67
internal medicine (66) 66
neoplasm staging (66) 66
non-hodgkin-lymphoma (65) 65
bendamustine hydrochloride - adverse effects (63) 63
b-cell (62) 62
immunotherapy (62) 62
diagnosis (59) 59
lymphoma, follicular - drug therapy (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1420) 1420
German (37) 37
Japanese (18) 18
Russian (13) 13
Polish (10) 10
French (8) 8
Spanish (6) 6
Chinese (2) 2
Czech (2) 2
Hungarian (2) 2
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5626 - 5626
Abstract Introduction Bendamustine (B) and Melflufen (Mel) are Non-Food and Drug Administration (FDA) approved novel alkylators that exert their cytotoxic... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4472 - 4472
Abstract Background: In patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), novel therapies are needed to prolong disease control.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5847 - 5847
Abstract Background and Aim: The incidence and outcomes of patients with cancer diagnoses are reported annually as SEERs in few but not all countries. Clinical... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4781 - 4781
Abstract Background: Recent introductions of multiple myeloma (MM) chemotherapy agents have improved response and survival rates, yet substantial unmet... 
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, p. 225
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1932 - 1938
Abstract Background Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic... 
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 10/2016, Volume 146, pp. 852 - 860
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, p. 86
Journal Article
R & D Focus Drug News, ISSN 1350-1135, 07/2019
Journal Article
Apoptosis, ISSN 1360-8185, 06/2017, Volume 22, Issue 6, pp. 827 - 840
Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis.... 
Bendamustine | Synergistic effect | Lymphoma | Ricolinostat | Apoptosis | MULTIPLE-MYELOMA | MULTICENTER | AGGRESOME FORMATION | ACY-1215 | ACETYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MECHANISMS | CELL BIOLOGY | THIOREDOXIN | IN-VIVO | LENALIDOMIDE | HISTONE DEACETYLASE INHIBITORS | Bendamustine Hydrochloride - therapeutic use | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Histone Deacetylase 6 - metabolism | Lymphoma - drug therapy | Mesenchymal Stromal Cells - cytology | Microtubules - metabolism | Tubulin - metabolism | Caspases - metabolism | Microtubules - drug effects | Interleukin-10 - metabolism | Lymphoma - pathology | Clone Cells | Proto-Oncogene Proteins c-akt - metabolism | Hydroxamic Acids - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Mesenchymal Stromal Cells - drug effects | Endoplasmic Reticulum Stress - drug effects | Histone Deacetylase 6 - antagonists & inhibitors | Cell Cycle Proteins - metabolism | Pyrimidines - pharmacology | Enzyme Activation - drug effects | Drug Synergism | Acetylation - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Bendamustine Hydrochloride - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Proto-Oncogene Proteins c-bcl-2 | Cell Cycle - drug effects
Journal Article
R & D Focus Drug News, ISSN 1350-1135, 04/2019
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3293 - 3299
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.